Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma
dc.authorid | GURMAN, Gunhan/0000-0002-1263-8947 | |
dc.authorid | Beksac, Meral/0000-0003-1797-8657 | |
dc.authorwosid | GURMAN, Gunhan/AAM-8863-2020 | |
dc.authorwosid | Beksac, Meral/D-6411-2013 | |
dc.contributor.author | Aydogdu, I | |
dc.contributor.author | Koc, H | |
dc.contributor.author | Ilhan, O | |
dc.contributor.author | Gurman, G | |
dc.contributor.author | Akan, H | |
dc.contributor.author | Beksac, M | |
dc.contributor.author | Konuk, N | |
dc.date.accessioned | 2024-08-04T20:11:57Z | |
dc.date.available | 2024-08-04T20:11:57Z | |
dc.date.issued | 1997 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | In recent years, more effective and less toxic treatment protocols have been developed to increase the cure rates in intermediate and high grade non-Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MWE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade NHL. Twenty-one patients (16 male, 5 female; age between 26 and 70 years) with NHL were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at the 48th month. Side effects including mild myelosuppression, nausea/vomiting and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL. | en_US |
dc.identifier.endpage | 213 | en_US |
dc.identifier.issn | 0017-6559 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 9408764 | en_US |
dc.identifier.scopus | 2-s2.0-0031464921 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 207 | en_US |
dc.identifier.uri | https://hdl.handle.net/11616/93097 | |
dc.identifier.volume | 28 | en_US |
dc.identifier.wos | WOS:A1997YK20900003 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Vsp Bv | en_US |
dc.relation.ispartof | Haematologia | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | non-Hodgkin's lymphoma | en_US |
dc.subject | combination chemotherapy | en_US |
dc.subject | ifosfamide | en_US |
dc.subject | mitoxantrone | en_US |
dc.title | Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma | en_US |
dc.type | Article | en_US |